Turkmenistan Medical Device Registration: Sample Submission and Import Exemption Rules

1. Key takeaways

The sample rules in Turkmenistan consist of two provisions: submission on demand, plus a statutory exemption from registration:

• Whether samples must be submitted: decided by the requirement of the competent authority, not at the applicant’s option;
• Import of samples for registration: within a quantity not exceeding 10 packages, samples are exempt from national registration (article 05).

Together, these two provisions form a closed loop of apply first, deliver samples later. The applicant does not need to hold the samples at the moment of submission, but must be ready to deliver them quickly once the authority asks. The loop rewards preparation: companies that keep registration-grade samples, labeling and documentation aligned and shelved in advance respond to a sample request in days, while unprepared applicants can lose weeks arranging import documents for a batch that the exemption threshold then constrains.

2. Legal basis

Law No. 319-V of January 12, 2016 carries the 10 package exemption threshold for samples imported for registration purposes, while the registration Regulation establishes that the demand for samples comes from the competent authority. The Law on Certification adds a parallel exemption for laboratory samples used in research, which matters for companies that need to import test quantities for local laboratory work outside the registration file itself.

3. Expert insights

Insight 1: on demand means the sample stage cannot be scheduled in advance, but it must be reserved for.

The regulatory wording is that samples are submitted as required by the competent authority. This makes the demand discretionary: it may not be required, or it may be required. The correct approach to scheduling is therefore to reserve a sample delivery window and to respond quickly once the authority makes its request. A reserved window that goes unused costs nothing; an unreserved window that turns out to be needed costs the difference between a planned import and an emergency one, including customs and logistics arrangements made under time pressure.

Insight 2: 10 packages is the ceiling of the exemption and a hard constraint on sample quantity.

If the competent authority requires a sample quantity exceeding 10 packages, the excess no longer enjoys exemption from national registration. In practice the quantity and purpose should be stated clearly in the sample delivery note, and the quantity should be kept within 10 packages where at all possible. When a larger quantity is genuinely unavoidable, the import consequences should be clarified with the authority before shipment, because the boundary is defined by the statute and not by the applicant’s convenience.

Insight 3: the sample stage introduces a stretch of time that does not count toward the 180 days.

As explained in article 09, the time consumed by laboratory analysis is not counted within the 180 calendar days. The entire span of sample delivery and analysis therefore sits outside the statutory period. This is one of the main sources of the gap between the statutory 180 days and the actual 6 to 18 months. Modeling the project on the statute alone produces optimistic dates that the laboratory stage will then contradict, so the delivery and testing span belongs in the baseline schedule from the outset.

Insight 4: the condition of the samples themselves can become a ground for rejection.

Article 38 discusses the remaining shelf life threshold at the import stage (practical estimate of 60%). Samples are subject to the same constraint. If the sample batch has too short a remaining shelf life, it may be returned at the laboratory stage, and a second delivery stretches the cycle further. Batch selection for samples should therefore apply the same remaining-life discipline as commercial import, with a margin for the time the samples will spend in queues at the laboratory.

Insight 5: the sample pathway differs between locally manufactured and imported products.

In the regulatory wording, the drug side requires that finished product samples and working standards be submitted together with the registration dossier; the device side is explicitly governed by the requirement of the competent authority. This difference indicates that sample requirements for devices are more flexible than for drugs, but also less certain. Flexibility is an advantage only for those who plan for it: the absence of a fixed device sample rule means the authority’s request, when it comes, defines the requirement, and the applicant must be structurally ready to comply.

4. Practical recommendations

1. Reserve a sample delivery window in the schedule, but do not wait for the samples to be ready before submitting the dossier.
2. Keep the sample quantity within 10 packages, and attach a statement of purpose.
3. Reserve shelf life margin in the sample batch, planning backwards from the remaining shelf life threshold.
4. Keep samples consistent with the dossier (model, batch number, label version), to avoid mismatches at the laboratory stage.
5. List sample delivery and analysis time separately, outside the 180 day model.

5. Verification checklist

• □ A sample delivery window has been reserved in the schedule.
• □ The sample quantity is within 10 packages, with a statement of purpose attached.
• □ The shelf life margin of the sample batch meets the import threshold.
• □ The model, batch number and label version of the samples match the dossier.
• □ The time for the sample stage has been listed separately, and is not counted within the 180 days.

Regulatory information verified as of October 30, 2026. The content of this document was checked against the provision of Law No. 319-V on the Supply of Medicines (January 12, 2016) that samples for registration not exceeding 10 packages are exempt from national registration, and against the Regulation on National Registration of Medicines and Medical Devices approved by the Ministry of Health (samples are submitted as required by the competent authority); the statement that laboratory analysis time is not counted within the 180 calendar days follows the treatment of article 09.

• Local resources in Turkmenistan: GRZAN can coordinate licensed local import entities and authorized representative resources, covering national registration submission, the consular legalization chain for documents, sample delivery, interfaces with mandatory TDS certification, and customs clearance support.
• Service scope: classification determination, selection of the registration pathway, preparation of national-format dossiers, consular legalization and notarization, preparation of testing and stability documentation, organization of GMP and ISO 13485 evidence, changes and renewal, vigilance and post-market maintenance.
• Contact: GRZAN supports manufacturers, importers and authorized representatives with registration in this country; reach us at info@grzanglobal.com.